Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by SATTVA S NEELAPU and LORETTA NASTOUPIL.
SATTVA S NEELAPU
Connection Strength
8.069
LORETTA NASTOUPIL
  1. Safety and activity of pembrolizumab in combination with rituximab in relapsed or refractory follicular lymphoma. Blood Adv. 2022 02 22; 6(4):1143-1151.
    View in: PubMed
    Score: 0.831
  2. Novel immunologic approaches in lymphoma: unleashing the brakes on the immune system. Curr Oncol Rep. 2015 Jul; 17(7):30.
    View in: PubMed
    Score: 0.524
  3. Safety and activity of lenalidomide in combination with obinutuzumab in patients with relapsed indolent non-Hodgkin lymphoma: a single group, open-label, phase?1/2?trial. EClinicalMedicine. 2024 Aug; 74:102747.
    View in: PubMed
    Score: 0.246
  4. Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 study. Cancer. 2024 03 15; 130(6):876-885.
    View in: PubMed
    Score: 0.234
  5. Impact of conditioning chemotherapy on lymphocyte kinetics and outcomes in LBCL patients treated with CAR T-cell therapy. Leukemia. 2022 Nov; 36(11):2669-2677.
    View in: PubMed
    Score: 0.216
  6. Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma. Haematologica. 2021 10 01; 106(10):2667-2672.
    View in: PubMed
    Score: 0.202
  7. Preclinical and phase I studies of KA2237, a selective and potent inhibitor of PI3K ?/d in relapsed refractory B cell lymphoma. Leuk Lymphoma. 2021 12; 62(14):3452-3462.
    View in: PubMed
    Score: 0.200
  8. Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma. Blood. 2021 06 10; 137(23):3272-3276.
    View in: PubMed
    Score: 0.198
  9. Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma. Blood Adv. 2020 07 14; 4(13):2871-2883.
    View in: PubMed
    Score: 0.186
  10. Impact of maintenance rituximab in patients with de novo transformed indolent B cell lymphoma. Leuk Lymphoma. 2020 12; 61(12):2985-2989.
    View in: PubMed
    Score: 0.185
  11. Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. J Clin Oncol. 2020 09 20; 38(27):3119-3128.
    View in: PubMed
    Score: 0.184
  12. Pretreatment SUVmax may influence the clinical benefit of BR over R-CHOP in patients with previously untreated FL. Leuk Lymphoma. 2020 06; 61(6):1380-1387.
    View in: PubMed
    Score: 0.180
  13. Pre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphoma. Haematologica. 2020 07; 105(7):1907-1913.
    View in: PubMed
    Score: 0.176
  14. Safety of CAR T-cell therapy in patients with B-cell lymphoma and chronic hepatitis B or C virus infection. Blood. 2019 06 27; 133(26):2800-2802.
    View in: PubMed
    Score: 0.171
  15. Positron emission tomography-computed tomography predictors of progression after DA-R-EPOCH for PMBCL. Blood Adv. 2018 06 12; 2(11):1334-1343.
    View in: PubMed
    Score: 0.161
  16. Diffuse large B-cell lymphoma in very elderly patients over 80 years old: Incorporating consolidative radiation therapy into management decisions. Adv Radiat Oncol. 2017 Jul-Sep; 2(3):370-380.
    View in: PubMed
    Score: 0.149
  17. High ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study. Br J Haematol. 2017 04; 177(2):263-270.
    View in: PubMed
    Score: 0.148
  18. Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphoma. Cancer. 2016 Oct 15; 122(20):3145-3151.
    View in: PubMed
    Score: 0.140
  19. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol. 2014 Nov; 15(12):1311-8.
    View in: PubMed
    Score: 0.125
  20. Characterization of lymphopenia and correlating the risk of cytopenias with dose and BM volume irradiated in aggressive B-cell lymphoma patients bridged with radiation therapy for CAR-T cell therapy. Int J Radiat Oncol Biol Phys. 2024 Sep 18.
    View in: PubMed
    Score: 0.062
  21. Outcomes and toxicities in patients with diffuse-large B cell lymphoma involving the gastrointestinal tract and digestive organs. Front Oncol. 2024; 14:1447020.
    View in: PubMed
    Score: 0.062
  22. Response-Adapted Ultralow-Dose Radiation Therapy for Orbital Indolent B-Cell Lymphoma: A Phase 2 Nonrandomized Controlled Trial. JAMA Oncol. 2024 Sep 01; 10(9):1195-1203.
    View in: PubMed
    Score: 0.062
  23. Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. J Clin Oncol. 2024 Oct 20; 42(30):3581-3592.
    View in: PubMed
    Score: 0.061
  24. Response-adapted ultra-low-dose 4 Gy radiation as definitive therapy of gastric MALT lymphoma: a single-centre, pilot trial. Lancet Haematol. 2024 Jul; 11(7):e521-e529.
    View in: PubMed
    Score: 0.061
  25. Effect of delayed cell infusion in patients with large B-cell lymphoma treated with chimeric antigen receptor T-cell therapy. Haematologica. 2024 05 01; 109(5):1460-1468.
    View in: PubMed
    Score: 0.060
  26. Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: results from the US Lymphoma CAR-T Consortium. Blood Adv. 2024 Feb 27; 8(4):1042-1050.
    View in: PubMed
    Score: 0.060
  27. Efficacy and safety of brexucabtagene autoleucel CAR T-cell therapy with BTK inhibitors in the treatment of relapsed mantle cell lymphoma with central nervous system involvement. Leuk Lymphoma. 2024 May; 65(5):669-673.
    View in: PubMed
    Score: 0.059
  28. A phase 1 study of prophylactic anakinra to mitigate ICANS in patients with large B-cell lymphoma. Blood Adv. 2023 11 14; 7(21):6785-6789.
    View in: PubMed
    Score: 0.059
  29. Real-world analysis of safety and efficacy of CAR T-cell therapy in lymphoma patients with decreased kidney function. Br J Haematol. 2024 01; 204(1):e11-e16.
    View in: PubMed
    Score: 0.058
  30. A single-cell atlas of CD19 chimeric antigen receptor T?cells. Cancer Cell. 2023 11 13; 41(11):1835-1837.
    View in: PubMed
    Score: 0.058
  31. Prolonged cytopenia following CD19 CAR T?cell therapy is linked with bone marrow infiltration of clonally expanded IFN?-expressing CD8 T?cells. Cell Rep Med. 2023 08 15; 4(8):101158.
    View in: PubMed
    Score: 0.058
  32. A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL. Blood Adv. 2023 04 11; 7(7):1137-1145.
    View in: PubMed
    Score: 0.056
  33. Axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma patients in complete metabolic response. Haematologica. 2023 04 01; 108(4):1163-1167.
    View in: PubMed
    Score: 0.056
  34. A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy. Nat Med. 2023 04; 29(4):906-916.
    View in: PubMed
    Score: 0.056
  35. A polyamine-centric, blood-based metabolite panel predictive of poor response to CAR-T cell therapy in large B cell lymphoma. Cell Rep Med. 2022 11 15; 3(11):100720.
    View in: PubMed
    Score: 0.055
  36. Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma. Blood Cancer Discov. 2022 09 06; 3(5):385-393.
    View in: PubMed
    Score: 0.054
  37. Follicular Lymphoma Microenvironment Characteristics Associated with Tumor Cell Mutations and MHC Class II Expression. Blood Cancer Discov. 2022 09 06; 3(5):428-443.
    View in: PubMed
    Score: 0.054
  38. Positron emission tomography derived metrics in relapsed or refractory large B-cell lymphoma with residual disease before autologous stem cell transplant. Br J Haematol. 2023 01; 200(1):35-44.
    View in: PubMed
    Score: 0.054
  39. Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma. J Clin Oncol. 2023 02 01; 41(4):745-755.
    View in: PubMed
    Score: 0.054
  40. Risk assessment with low-pass whole-genome sequencing of cell-free DNA before CD19 CAR T-cell therapy for large B-cell lymphoma. Blood. 2022 08 04; 140(5):504-515.
    View in: PubMed
    Score: 0.054
  41. Cardiovascular events in patients treated with chimeric antigen receptor T-cell therapy for aggressive B-cell lymphoma. Haematologica. 2022 07 01; 107(7):1555-1566.
    View in: PubMed
    Score: 0.053
  42. SIRPa+ macrophages are increased in patients with FL who progress or relapse after frontline lenalidomide and rituximab. Blood Adv. 2022 06 14; 6(11):3286-3293.
    View in: PubMed
    Score: 0.053
  43. Severity of Cytokine Release Syndrome Influences Outcome After Axicabtagene Ciloleucel for Large B cell Lymphoma: Results from the US Lymphoma CAR-T Consortium. Clin Lymphoma Myeloma Leuk. 2022 10; 22(10):753-759.
    View in: PubMed
    Score: 0.053
  44. Day 30 SUVmax predicts progression in patients with lymphoma achieving PR/SD after CAR T-cell therapy. Blood Adv. 2022 05 10; 6(9):2867-2871.
    View in: PubMed
    Score: 0.053
  45. Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphoma. Haematologica. 2022 03 01; 107(3):690-701.
    View in: PubMed
    Score: 0.052
  46. A prospective study on early PET/CT scans during the first cycle of salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma. Leuk Lymphoma. 2022 01; 63(1):74-83.
    View in: PubMed
    Score: 0.050
  47. CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity. Blood Adv. 2021 07 27; 5(14):2799-2806.
    View in: PubMed
    Score: 0.050
  48. Prognostic value of disease distribution in secondary central nervous system diffuse large B cell lymphoma treated with radiation therapy. Leuk Lymphoma. 2021 10; 62(10):2400-2407.
    View in: PubMed
    Score: 0.049
  49. Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy. Blood. 2021 04 01; 137(13):1832-1835.
    View in: PubMed
    Score: 0.049
  50. Radiation and CAR T-cell Therapy in Lymphoma: Future Frontiers and Potential Opportunities for Synergy. Front Oncol. 2021; 11:648655.
    View in: PubMed
    Score: 0.049
  51. Long-term follow-up of lenalidomide and rituximab as initial treatment of follicular lymphoma. Blood. 2021 02 25; 137(8):1124-1129.
    View in: PubMed
    Score: 0.048
  52. The impact of cell-of-origin, MYC/Bcl-2 dual expression and MYC rearrangement on disease relapse among early stage diffuse large B-cell lymphoma patients treated with combined modality therapy. Leuk Lymphoma. 2021 06; 62(6):1361-1369.
    View in: PubMed
    Score: 0.048
  53. A Prospective Trial of Radiation Therapy Efficacy and Toxicity for Localized Mucosa-associated Lymphoid Tissue (MALT) Lymphoma. Int J Radiat Oncol Biol Phys. 2021 04 01; 109(5):1414-1420.
    View in: PubMed
    Score: 0.048
  54. Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. Nat Med. 2020 12; 26(12):1878-1887.
    View in: PubMed
    Score: 0.047
  55. Initial report of a phase II study with R-FND followed by ibritumomab tiuxetan radioimmunotherapy and rituximab maintenance in patients with untreated high-risk follicular lymphoma. Leuk Lymphoma. 2021 01; 62(1):58-67.
    View in: PubMed
    Score: 0.047
  56. Assessment of Radiation Doses Delivered to Organs at Risk Among Patients With Early-Stage Favorable Hodgkin Lymphoma Treated With Contemporary Radiation Therapy. JAMA Netw Open. 2020 09 01; 3(9):e2013935.
    View in: PubMed
    Score: 0.047
  57. Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 2020 08 25; 4(16):3943-3951.
    View in: PubMed
    Score: 0.047
  58. Clinical efficacy of anakinra to mitigate CAR T-cell therapy-associated toxicity in large B-cell lymphoma. Blood Adv. 2020 07 14; 4(13):3123-3127.
    View in: PubMed
    Score: 0.046
  59. Ibrutinib-based therapy for the treatment of marginal zone lymphoma with central nervous system involvement. Leuk Lymphoma. 2020 12; 61(12):2980-2984.
    View in: PubMed
    Score: 0.046
  60. Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients. Am J Hematol. 2020 06; 95(6):623-629.
    View in: PubMed
    Score: 0.046
  61. Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL. Blood Adv. 2020 03 24; 4(6):1038-1050.
    View in: PubMed
    Score: 0.045
  62. The combination of ibrutinib and rituximab demonstrates activity in first-line follicular lymphoma. Br J Haematol. 2020 05; 189(4):650-660.
    View in: PubMed
    Score: 0.045
  63. Imaging Surveillance of Limited-stage Classic Hodgkin Lymphoma Patients After PET-CT-documented First Remission. Clin Lymphoma Myeloma Leuk. 2020 08; 20(8):533-541.
    View in: PubMed
    Score: 0.045
  64. Partial omission of bleomycin for early-stage Hodgkin lymphoma patients treated with combined modality therapy: Does incomplete ABVD lead to inferior outcomes? EJHaem. 2020 Jul; 1(1):272-276.
    View in: PubMed
    Score: 0.045
  65. Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma. Cancer Discov. 2020 03; 10(3):440-459.
    View in: PubMed
    Score: 0.045
  66. De novo CD5+ diffuse large B-cell lymphoma, NOS: clinical characteristics and outcomes in rituximab era. Leuk Lymphoma. 2020 02; 61(2):328-336.
    View in: PubMed
    Score: 0.044
  67. Radiation therapy for salivary gland MALT lymphoma: ultra-low dose treatment achieves encouraging early outcomes and spares salivary function. Leuk Lymphoma. 2020 01; 61(1):171-175.
    View in: PubMed
    Score: 0.043
  68. Additional therapy improves outcomes in completely resected, limited-stage follicular lymphoma. Leuk Lymphoma. 2019 12; 60(13):3258-3265.
    View in: PubMed
    Score: 0.043
  69. Favorable outcomes with de-escalated radiation therapy for limited-stage nodular lymphocyte-predominant Hodgkin lymphoma. Blood Adv. 2019 05 14; 3(9):1356-1367.
    View in: PubMed
    Score: 0.043
  70. Lenalidomide plus rituximab (R2 ) in previously untreated marginal zone lymphoma: subgroup analysis and long-term follow-up of an open-label phase 2 trial. Br J Haematol. 2019 06; 185(5):874-882.
    View in: PubMed
    Score: 0.042
  71. Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma. Head Neck. 2019 May; 41(5):1546.
    View in: PubMed
    Score: 0.042
  72. Early Stage Extranodal Follicular Lymphoma: Characteristics, Management, and Outcomes. Clin Lymphoma Myeloma Leuk. 2019 06; 19(6):381-389.
    View in: PubMed
    Score: 0.042
  73. Outcomes After Reduced-Dose Intensity Modulated Radiation Therapy for Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma. Int J Radiat Oncol Biol Phys. 2019 06 01; 104(2):447-455.
    View in: PubMed
    Score: 0.042
  74. Stage I non-Hodgkin lymphoma: no plateau in disease-specific survival ? Ann Hematol. 2019 May; 98(5):1169-1176.
    View in: PubMed
    Score: 0.042
  75. Hitting a Moving Target: Successful Management of Diffuse Large B-cell Lymphoma Involving the Mesentery With Volumetric Image-guided Intensity Modulated Radiation Therapy. Clin Lymphoma Myeloma Leuk. 2019 01; 19(1):e51-e61.
    View in: PubMed
    Score: 0.041
  76. Response-adapted radiation therapy for newly diagnosed primary diffuse large B-cell lymphoma of the CNS treated with methotrexate-based systemic therapy. Adv Radiat Oncol. 2018 Oct-Dec; 3(4):639-646.
    View in: PubMed
    Score: 0.040
  77. Stage I Non-Hodgkin Lymphoma: difference in survival outcome by primary extranodal site of involvement. Br J Haematol. 2019 04; 185(2):334-338.
    View in: PubMed
    Score: 0.040
  78. Impact of histologic subtypes and treatment modality among patients with primary central nervous system lymphoma: a SEER database analysis. Oncotarget. 2018 Jun 22; 9(48):28897-28902.
    View in: PubMed
    Score: 0.040
  79. The risk of central nervous system relapses in patients with peripheral T-cell lymphoma. PLoS One. 2018; 13(3):e0191461.
    View in: PubMed
    Score: 0.039
  80. Predictors of Hypothyroidism in Hodgkin Lymphoma Survivors After Intensity Modulated Versus 3-Dimensional Radiation Therapy. Int J Radiat Oncol Biol Phys. 2018 07 01; 101(3):530-540.
    View in: PubMed
    Score: 0.039
  81. Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma. Head Neck. 2018 06; 40(6):1335.
    View in: PubMed
    Score: 0.039
  82. Radiation Therapy as an Effective Salvage Strategy for Secondary CNS Lymphoma. Int J Radiat Oncol Biol Phys. 2018 04 01; 100(5):1146-1154.
    View in: PubMed
    Score: 0.039
  83. Long-Term Remissions of Patients With Follicular Lymphoma Grade 3 Treated With R-CHOP. Clin Lymphoma Myeloma Leuk. 2018 01; 18(1):e103-e108.
    View in: PubMed
    Score: 0.039
  84. Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphoma. Leuk Lymphoma. 2018 04; 59(4):863-870.
    View in: PubMed
    Score: 0.038
  85. Encouraging activity for R-CHOP in advanced stage nodular lymphocyte-predominant Hodgkin lymphoma. Blood. 2017 07 27; 130(4):472-477.
    View in: PubMed
    Score: 0.037
  86. Radiation therapy improves survival in patients with testicular diffuse large B-cell lymphoma. Leuk Lymphoma. 2017 12; 58(12):2833-2844.
    View in: PubMed
    Score: 0.037
  87. Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma. Head Neck. 2017 06; 39(6):1095-1100.
    View in: PubMed
    Score: 0.037
  88. The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma. Br J Haematol. 2017 03; 176(5):750-758.
    View in: PubMed
    Score: 0.036
  89. Maternal and Fetal Outcomes After Therapy for Hodgkin or Non-Hodgkin Lymphoma Diagnosed During Pregnancy. JAMA Oncol. 2016 Aug 01; 2(8):1065-9.
    View in: PubMed
    Score: 0.035
  90. Prognostic significance of baseline peripheral absolute neutrophil, monocyte and serum ?2-microglobulin level in patients with diffuse large b-cell lymphoma: a new prognostic model. Br J Haematol. 2016 Oct; 175(2):290-299.
    View in: PubMed
    Score: 0.035
  91. Role of the tumor microenvironment in mature B-cell lymphoid malignancies. Haematologica. 2016 05; 101(5):531-40.
    View in: PubMed
    Score: 0.035
  92. Premature closure of a phase II study of bendamustine, mitoxantrone and rituximab for patients with untreated high-risk follicular lymphoma due to severe haematological and infectious toxicity. Br J Haematol. 2016 11; 175(3):531-533.
    View in: PubMed
    Score: 0.034
  93. Characteristics and management of rash following lenalidomide and rituximab in patients with untreated indolent non-Hodgkin lymphoma. Haematologica. 2015 Nov; 100(11):e454-7.
    View in: PubMed
    Score: 0.033
  94. Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma. Blood. 2015 May 21; 125(21):3357-9.
    View in: PubMed
    Score: 0.032
  95. Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by 18fluorodeoxyglucose positron emission tomography. Int J Radiat Oncol Biol Phys. 2015 May 01; 92(1):113-21.
    View in: PubMed
    Score: 0.032
  96. Double hit lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol. 2014 Sep; 166(6):891-901.
    View in: PubMed
    Score: 0.030
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.